Welcome to our dedicated page for Enochian Biosciences news (Ticker: ENOB), a resource for investors and traders seeking the latest updates and insights on Enochian Biosciences stock.
Enochian Biosciences, Inc. (ENOB) is a pioneering biopharmaceutical company headquartered in Los Angeles, California. Formerly known as Dandrit Biotech USA Inc., Enochian focuses on developing and commercializing groundbreaking therapies aimed at transforming immunotherapy treatments for HIV/AIDS and cancer.
The company's leading candidate, ENO-1001, is in the pre-Investigational New Drug (pre-IND) stage and has potential as a sterilizing cure for HIV/AIDS. In addition to ENO-1001, Enochian is working on ENO-2001, an HIV vaccine currently in the preclinical stage. The company is also focusing on innovative compounds such as ENO-4001 (a phase three asset), ENO-4002, ENO-5001, and ENO-3001 for the prevention of relapse in colon cancer patients.
Enochian Biosciences has recently faced a significant event where their Annual Meeting required adjournment due to the lack of a quorum. The meeting has been rescheduled to July 21, 2023, at 12:00 p.m. (Eastern Time). The company continues to solicit votes from its stockholders to meet the required quorum. Valid proxies and votes already submitted will still be effective unless revoked, and the company encourages all eligible stockholders to participate.
Enochian Biosciences operates with a clear focus on research and development, continually working on their clinical trials and product development activities. The company is actively engaged in securing regulatory approvals for its products and is strategically positioned for potential future growth. Investors are advised to stay updated with the company's latest developments and filings with the United States Securities and Exchange Commission (SEC).
For more information, stockholders and interested parties can access the company's proxy statement and annual reports, or attend the virtual Annual Meeting.
Enochian BioSciences announced promising results from initial preclinical studies on its pancreatic cancer treatment platform. The company received a U.S. patent for its innovative therapy that utilizes gene-enhanced dendritic cells to stimulate an immune response against tumors. In studies involving humanized mice, the candidate reduced tumor weight by over 75% and volume by more than 85%, suggesting significant efficacy. Plans for further studies and potential FDA submission in 2023 indicate a commitment to rapid development in addressing this critical health issue.
Enochian BioSciences (NASDAQ: ENOB) appointed Dr. Richard Whitley, M.D., as its Senior Scientific Advisor. With a robust background in virology and extensive experience in developing antiviral therapies, Dr. Whitley aims to contribute significantly to Enochian's research endeavors. CEO Dr. Mark Dybul emphasized the importance of Dr. Whitley’s expertise in advancing the company's research pipelines, particularly the innovative “Hijack” RNA approach. Dr. Whitley's accolades include multiple publications and significant contributions during the COVID-19 pandemic.
Enochian BioSciences (NASDAQ: ENOB) recently completed an internal review of its scientific data, confirming the integrity of its HIV and cancer pipelines. However, the review revealed that former advisor Serhat Gumrukçu falsified animal data for COVID-19 and HBV treatments, prompting the company to pursue legal action. Despite the setback, Enochian remains committed to advancing its therapies while assessing its data verification processes. The company continues to receive recognition from scientific leaders for its innovative approaches to public health challenges.
Enochian BioSciences (NASDAQ: ENOB) is advancing its innovative approaches in tackling major health issues such as HIV, cancer, and COVID-19. The company aims to develop potential life-saving therapies, with endorsements from prominent scientists who have conducted pivotal studies on its pipelines. Notable figures include Dr. Philippe Gallay and Dr. Anahid Jewett, who emphasize the promising data and potential for robust immune responses. Enochian's management is noted for its speed in progressing towards human studies while addressing the challenges posed by emerging virus variants.
Enochian BioSciences' Board expresses confidence in the company's future following the arrest of Dr. Serhat Gumrukçu, co-founder and inventor, on charges unrelated to the company. The Board confirmed that Gumrukçu had no formal role in the company and emphasized the strength of the current management and research teams. The company remains committed to advancing its innovative technologies and pipeline, with no negative impact from the arrest reported. Additionally, Greg Alton has been appointed as the Lead Independent Board member to support the company's strategic direction.
Enochian BioSciences (NASDAQ: ENOB) has appointed Dr. François Binette as Executive Vice President for Research and Development. With over 25 years of experience in Advanced Therapy and Regenerative Medicine, Dr. Binette previously served as Senior VP of Product Development at Lineage Cell Therapeutics, leading significant allogenic cell therapy initiatives. His expertise is expected to enhance Enochian's pipeline and facilitate progress towards regulatory and clinical milestones, as highlighted by CEO Dr. Mark Dybul.
Enochian BioSciences (NASDAQ: ENOB) announced the appointment of Greg Duczynski as Senior Vice President for Clinical Operations. Duczynski brings over 32 years of experience from Pfizer, where he held various leadership roles in Clinical Development and Operations. His expertise includes managing international gene therapy trials. CEO Dr. Mark Dybul emphasized Duczynski's significant background as a valuable addition as Enochian prepares to initiate several clinical studies. Duczynski expressed enthusiasm about Enochian's potential for growth with its innovative technologies and promising pipelines.
Dr. Serhat Gumrukçu, co-founder of Enochian BioSciences, presented innovative clinical strategies for treating HIV and cancer at the Innate Killer Summit in San Diego. His approach includes using Natural Killer (NK) and Gamma Delta T cells, showing prolonged HIV control in a patient resistant to antiviral drugs. The presentation also featured promising results from a case where glioblastoma patients achieved tumor-free status after treatment with NK and dendritic cells. Enochian BioSciences holds the technology's intellectual property, aiming to enhance immune responses against cancers.
Enochian BioSciences (NASDAQ: ENOB) announced that Dr. Serhat Gumrukçu delivered a Plenary Lecture at the Innate Killer Summit in San Diego. His presentation highlighted clinical strategies for enhancing the immune response, showcasing a novel approach using Natural Killer (NK) cells and Gamma Delta T-cells, which successfully controlled HIV for 365 days in a patient resistant to traditional antiviral drugs. The company also shared data on patients with glioblastoma and optic tract glioma, reporting significant positive outcomes. Enochian BioSciences holds exclusive licenses for these innovative therapies.
Enochian BioSciences (NASDAQ: ENOB) has granted an exclusive sub-license for a proprietary technology aimed at enhancing an anti-HIV CAR-T therapy being studied by Caring Cross. This partnership includes a profit-sharing agreement. The CAR-T approach has shown promising results in animal models and has received FDA approval to proceed with clinical studies funded by the California Institute of Regenerative Medicine. Executives from both organizations expressed optimism about the technology's potential to improve therapy effectiveness and accessibility.
FAQ
What is the market cap of Enochian Biosciences (ENOB)?
What does Enochian Biosciences do?
Where is Enochian Biosciences headquartered?
What is ENO-1001?
What stage is ENO-2001 in?
What are some other compounds Enochian is working on?
When is the rescheduled Annual Meeting?
How can stockholders vote for the proposals?
Who is helping Enochian with the voting process?
Where can I find the proxy statement and annual reports?
How can I attend the virtual Annual Meeting?
